Abstract: Disclosed herein are compositions and methods for inhibiting abnormal angiogenesis in the eye, particularly in the retina. The methods include administering to subject in need of treatment for pathological angiogenesis of the eye a pharmaceutically effective amount of an inhibitor of the receptor activity of the S1P2 receptor. Also included are compositions including an S1P2 receptor antagonist and an opthalmically acceptable excipient.